A combination of xanomeline with trospium as an innovative pharmacological strategy for schizophrenia

Treating schizophrenia involves many difficulties. It is estimated that around 20-33% of patients do not respond to the proposed therapy with available antipsychotic drugs, which is associated with the occurrence of problems with everyday functioning. Currently used drugs are mainly characterized by regulation of the dopaminergic system. This review compiles information on the effectiveness of a complex drug (xanomeline with trospium) for schizophrenia with a new mechanism of action. The drug, known as KarXT, targets proteins in the brain known as muscarinic receptors. Activation of these receptors suppresses the release of the neurotransmitter dopamine, whose deficiency is associated with the occurrence of key symptoms of schizophrenia, such as hallucinations and delusions. The drug offers hope for better efficacy in treating schizophrenia and better tolerability than current therapies. On September 27, 2024, the FDA approved Cobenfy (known as KarXT - xanomeline with trospium), a new oral medication for adults with schizophrenia. The approval of Cobenfy is a landmark moment in the treatment of schizophrenia because it offers a new, innovative treatment option for this challenging condition.